Free Trial
NYSE:AORT

Artivion Q3 2025 Earnings Report

Artivion logo
$40.21 -0.14 (-0.35%)
Closing price 10/10/2025 03:59 PM Eastern
Extended Trading
$39.75 -0.46 (-1.14%)
As of 10/10/2025 07:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Artivion EPS Results

Actual EPS
N/A
Consensus EPS
$0.14
Beat/Miss
N/A
One Year Ago EPS
N/A

Artivion Revenue Results

Actual Revenue
N/A
Expected Revenue
$110.71 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Artivion Announcement Details

Quarter
Q3 2025
Time
Before Market Opens
Conference Call Date
Thursday, November 6, 2025
Conference Call Time
4:30PM ET

Conference Call Resources

Artivion Earnings Headlines

$100 Trillion “AI Metal” Found in American Ghost Town
Jeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could be the biggest technology story of this decade. In short, he believes what he's holding in his hand is the key to the $100 trillion AI boom… And only one company here in the U.S. can mine this obscure metal.tc pixel
Artivion (NYSE:AORT) Price Target Raised to $46.00
See More Artivion Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Artivion? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Artivion and other key companies, straight to your email.

About Artivion

Artivion (NYSE:AORT) (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation. Headquartered in Kennesaw, Georgia, Artivion operates manufacturing and processing facilities in the United States and Europe, with commercial teams serving hospitals and surgical centers across North America, Latin America, Europe, the Middle East and Asia-Pacific. Its global footprint is supported by direct sales operations and distribution partnerships that deliver both off-the-shelf and custom tissue solutions to clinicians worldwide.

Leadership at Artivion is focused on expanding the company’s product pipeline through research and development initiatives and strategic acquisitions. Under the direction of CEO Paul F. Le Gars, the company has pursued regulatory approvals across multiple markets and invested in next-generation tissue processing technologies. Through this combination of biologic innovation and device engineering, Artivion aims to address unmet clinical needs in cardiovascular surgery and improve patient outcomes over the long term.

View Artivion Profile

More Earnings Resources from MarketBeat